Interestingly within that NIH "Media Advisory" they attribute information to this article:

https://jamanetwork.com/journals/jama/fullart...erm=051820

While CytoDyn's not listed at the bottom, among the "Additional Contributors" to that article Gilead is... and now of course we're hearing about a joint trial ( CytoDyn & Gilead )...

While not sure who or what entity (entities) initiated this joint effort, it leads me to think federal funding to CytoDyn is contingent on this joint trial.

I hope the right questions are asked should there be a Proactive interview with Dr. Pourhassan (of course it may depend on what he is 'allowed' to say also, hmmm).